Home/Filings/4/A/0001127602-22-001456
4/A//SEC Filing

Doyle Anthony 4/A

Accession 0001127602-22-001456

CIK 0000882796other

Filed

Jan 12, 7:00 PM ET

Accepted

Jan 13, 4:40 PM ET

Size

4.7 KB

Accession

0001127602-22-001456

Insider Transaction Report

Form 4/AAmended
Period: 2021-12-14
Doyle Anthony
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2021-12-14+75,000168,719 total
Footnotes (1)
  • [F1]The number of restricted stock units awarded to the reporting person on December 14, 2021 was overstated in the original Form 4 due to an administrative error. This amendment corrects the error and reflects the corrected amount of restricted stock units awarded to the reporting person on such date.

Issuer

BIOCRYST PHARMACEUTICALS INC

CIK 0000882796

Entity typeother

Related Parties

1
  • filerCIK 0001808688

Filing Metadata

Form type
4/A
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 4:40 PM ET
Size
4.7 KB